US Stocks Movement: Moderna surges on October 9, included in Nasdaq 100 + Cancer Vaccine

Moderna’s Surge on October 9: An Analysis

Keywords: Included in Nasdaq-100, Cancer Vaccine

1. On October 9, Moderna was officially included in the Nasdaq-100 Index, replacing Warner Bros. Discovery; this index is tracked by more than 200 investment products with assets under management exceeding 800 billion USD.

2. On October 7, the company, together with Merck and Tempus, expanded their multi-year partnership to support tumor sample collection, sequencing, as well as therapy design and production for the potential commercialization of the personalized neoantigen therapy intismeran autogene.

3. On October 7, Morgan Stanley raised Moderna’s target price from 89 USD to 95 USD; the company’s phase III study for personalized cancer therapy in partnership with Merck has achieved its primary endpoint of recurrence-free survival, and five-year data shows a 49% reduction in recurrence or death risk compared to Keytruda monotherapy.

(Disclaimer: This content is collected and summarized from publicly available information by AI technology. It is for reference only and does not constitute investment advice.)